Solventum Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bryan C. Hanson
- Full Time Employees
- 20,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1750 Yankee Doodle Road Eagan MN United States of America 55121
- IPO Date
- Apr 1, 2024
- CIK
- 0001964738
- Website
- solventum.com
- Similar Companies
- Business
- Solventum Corporation (NYSE: SOLV) develops, manufactures and commercializes healthcare solutions at the intersection of health, material and data science, including advanced wound care such as negative pressure wound therapy and surgical incision management; infection prevention and skin integrity products; dental and orthodontic bonding systems and consumables; revenue cycle management and health information systems software; and purification and filtration solutions for biopharmaceutical manufacturers. The company, spun off from 3M and became independently publicly traded on April 1, 2024, after incorporation in 2023 as a successor to 3M's health care business with over 70 years of history, maintains headquarters in St. Paul, Minnesota, and employs more than 20,000 people across approximately 38 countries with significant operations in the United States (over 50% of sales), EMEA, Asia-Pacific including China, and other international markets; it operates through three primary segments post recent divestiture, MedSurg (largest, encompassing advanced wound care, oral care and medical device components), Dental Solutions, and Health Information Systems, serving hospitals, clinics, dental professionals, biopharma firms and healthcare providers. Recent major changes include the February 2025 announcement and subsequent completion of the $4.1 billion sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. expected by end-2025 for net proceeds of about $3.4 billion primarily to reduce debt as part of its multi-phase transformation plan following independence; alongside scheduling an Investor Day in March 2025 to outline long-range strategy and a definitive agreement to acquire Acera Surgical to bolster surgical technologies and patient outcomes.
Nelson Peltz and Trian Take a New Position: The Turnaround Thesis
Why Solventum (SOLV) is a Top Stock for the Long-Term
Arrowstreet Capital Limited Partnership Has $57.70 Million Stake in Solventum Corporation $SOLV
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV Energy to Report Second Quarter 2026 Financial Results on August 13, 2026
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
Solving A Lackluster Growth Outlook Should Be Solventum's Next Priority
SOLV Energy: The Pullback Makes The Buy Case Stronger
Why Solventum (SOLV) is a Top Stock for the Long-Term
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Solventum Trends for 2026: AI Coding, Tariffs, and Margins
SOLV Energy Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares of Class A Common Stock
Solventum Corporation (SOLV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
SOLV Energy Scales Up, Now Supporting Multiple 600+ MW Solar and Battery Projects Totaling More than 4 GW Across the U.S.
SOLV Energy Announces Pricing of Upsized Public Offering of Class A Common Stock
Solventum to Participate in the 2026 Jefferies Healthcare Conference
SOLV Energy Announces Launch of Public Offering of Class A Common Stock
SOLV Energy, Inc. (MWH) Q1 2026 Earnings Call Transcript
SOLV or HQY: Which Is the Better Value Stock Right Now?